Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate)
Brand Names: Solstice Pain Relieving
Methodology & AI Transparency ⓘ
Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Camphor, Menthol, Methyl Salicylate (cross-referenced at /meds/camphor-menthol-methyl-salicylate) and registered by MADISON ONE ACME INC, Solstice Pain Relieving operates as a over-the-counter branded non-standardized plant allergenic extract therapy (RxNorm 1793147-B55614210; NDC 55614-210, 55614-310).
- 2 Real-world patient consensus: Commercial Solstice Pain Relieving monograph (3.1 g/100g / 6 g/100g Patch) cross-indexed with generic Camphor, Menthol, Methyl Salicylate for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $11.93 discount cash to $34.50 walk-in retail (NADAC $0.0477/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate): nausea (8.6%), headache (8.2%), dizziness (5.6%).
Ask our AI Specialists anything about Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate)
Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Camphor, Menthol, Methyl Salicylate (cross-referenced at /meds/camphor-menthol-methyl-salicylate) and registered by MADISON ONE ACME INC, Solstice Pain Relieving operates as a over-the-counter branded non-standardized plant allergenic extract therapy (RxNorm 1793147-B55614210; NDC 55614-210, 55614-310). Under 2025-11-10 FDA labeling for 3.1 g/100g / 6 g/100g Patch; Therapeutic monitoring titration for Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) (non-standardized plant allergenic extract), Uses For the temporary relief of minor aches and pains of muscles and joints due to: simple backache arthritis strains
Bioactive Camphor, Menthol, Methyl Salicylate within Solstice Pain Relieving governs non-standardized plant allergenic extract target modulation with class-characteristic hepatorenal disposition. Commercialized across 3.1 g/100g / 6 g/100g Patch; Therapeutic monitoring titration for Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) (non-standardized plant allergenic extract) (registered by MADISON ONE ACME INC, SPL 2025-11-10), Solstice Pain Relieving combines branded dosage-form consistency (NDC 55614-210, 55614-310) with transparent cash-pay comparisons spanning $11.93 to $34.50.
Following administration (3.1 g/100g / 6 g/100g Patch), Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) achieves Oral fraction absorbed ranges from 47% to 59% (Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) 3.1) bioavailability and oral tmax achieved within 2 to 3 hours following solstice pain relieving (camphor, menthol, methyl salicylate) ingestion onset, governed by a Mean elimination half-life of 10 to 14 hours across adult Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of solstice pain relieving (camphor, menthol, methyl salicylate).
Before initiating Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) at 3.1 g/100g / 6 g/100g Patch, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to solstice pain relieving (camphor, menthol, methyl salicylate); clinical scenarios where non-standardized plant allergenic extract exposure from solstice pain relieving (camphor, menthol, methyl salicylate) poses unacceptable risk. Logged tolerability patterns center on nausea (8.6% of reports), headache (8.2% of reports), dizziness (5.6% of reports).
Verify medication reconciliation lists so Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) is not inadvertently duplicated with another non-standardized plant allergenic extract.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate)
- Clinical scenarios where non-standardized plant allergenic extract exposure from Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) poses unacceptable risk
Logged Side-Effect Incidence (15 Reports)
Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Maribavir for refractory cytomegalovirus infection (with or without resistance): What a 211-Participant Study Found Consistent with findings in the overall SOLSTICE population, this subgroup analysis of SOT recipients demonstrated greater effectiveness of maribavir for cytomegalovirus viremia. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2025-06-15 • Phase III Randomized Trial | N = 211 | 82/100 | PMID 39613120 ↗ |
| Can This Approach Help? Inside the Latest Research on Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Median (range) time from treatment start to death was 30.5 (3-123) days. Transplant international : official journal of the European Society for Organ Transplantation • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41384277 ↗ |
| New Insights on Chart review of transplant recipients with cytomegalovirus infection who received: What a 234-Participant Study Found Overall mortality at 52 weeks post-maribavir treatment initiation in this sub-cohort of patients from the SOLSTICE trial was lower than that previously reported for similar populations treated with conventional therapies for... Antiviral therapy • 2023-10-15 • Phase III Randomized Trial | N = 234 | 82/100 | PMID 37657421 ↗ |
Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0477/unit (~$1.43/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $11.93 / mo | View logs ↓ |
Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) RxNorm Concept ID | 1793147-B55614210 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0477 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $11.93 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) integrating DailyMed SPL (2025-11-10), CMS NADAC ($0.0477/unit), and 15 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Solstice Pain Relieving (Camphor, Menthol, Methyl Salicylate) community threads and patient logs by age, biological sex, dosage, and treatment duration.